Simplify Asset Management Inc. Acquires Shares of 385,188 ADMA Biologics, Inc. (NASDAQ:ADMA)

Simplify Asset Management Inc. bought a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 385,188 shares of the biotechnology company’s stock, valued at approximately $6,606,000. ADMA Biologics comprises about 0.3% of Simplify Asset Management Inc.’s investment portfolio, making the stock its 19th largest holding. Simplify Asset Management Inc. owned 0.16% of ADMA Biologics as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Healthcare of Ontario Pension Plan Trust Fund increased its position in ADMA Biologics by 13.9% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company’s stock worth $13,171,000 after purchasing an additional 80,400 shares during the last quarter. Lord Abbett & CO. LLC purchased a new stake in shares of ADMA Biologics in the 3rd quarter valued at approximately $61,858,000. Raymond James Financial Inc. acquired a new stake in shares of ADMA Biologics during the 4th quarter worth approximately $19,076,000. EWG Elevate Inc. purchased a new stake in shares of ADMA Biologics during the 4th quarter valued at approximately $480,000. Finally, Citigroup Inc. raised its position in shares of ADMA Biologics by 251.7% during the 3rd quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company’s stock valued at $7,741,000 after buying an additional 277,138 shares during the period. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 target price on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Price Performance

Shares of ADMA opened at $19.80 on Friday. The firm has a 50-day simple moving average of $16.76 and a two-hundred day simple moving average of $18.04. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a 1-year low of $5.90 and a 1-year high of $23.64. The stock has a market cap of $4.68 billion, a PE ratio of 70.71 and a beta of 0.60.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.